Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Reports First Quarter 2017 Financial Results
Phase 3 FORT study of RE-024 in PKAN to begin dosing mid-2017 Protocol development underway for pivotal Phase 3 trial of sparsentan in FSGS First quarter revenues rose 16 percent to $34 million SAN DIEGO , May 04, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc.
View HTML
Toggle Summary Retrophin to Report First Quarter 2017 Financial Results
SAN DIEGO , April 20, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report first quarter 2017 financial results on Thursday, May 4, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin Appoints Ron Squarer to Board of Directors
SAN DIEGO , April 12, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc.  (NASDAQ:RTRX) today announced the appointment of Ron Squarer to the Company's Board of Directors, effective immediately. Mr. Squarer is chief executive officer and a director of Array BioPharma Inc., a biopharmaceutical company focused
View HTML
Toggle Summary John A. Orwin Joins Retrophin Board of Directors
SAN DIEGO , March 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc.  (NASDAQ:RTRX) today announced the appointment of John A. Orwin to the Company's Board of Directors, effective immediately. Mr. Orwin currently serves as chief executive officer of Relypsa, Inc.
View HTML
Toggle Summary Retrophin to Present at the Barclays Global Healthcare Conference
SAN DIEGO , March 07, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced that Stephen Aselage , chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 15, 2017 at 2:05 p.m. ET .
View HTML
Toggle Summary Retrophin Provides Sparsentan Regulatory Update; Reports Fourth Quarter and Full Year 2016 Financial Results
Phase 3 trial of sparsentan in FSGS to initiate in second half of 2017; Interim analysis of proteinuria to serve as basis for NDA filing for accelerated approval Full year 2016 revenue grew 34% over 2015 to $134 million Conference call today at 5:00 p.m.
View HTML
Toggle Summary Retrophin Joins Participants from Around the World in Recognizing Rare Disease Day® 2017
Retrophin Joins Participants from Around the World in Recognizing Rare Disease Day ® 2017   SAN DIEGO (February 28, 2017) – Retrophin, Inc. (NASDAQ: RTRX) today joins patients, advocates, healthcare professionals, researchers, public health authorities and the biopharmaceutical
View HTML
Toggle Summary Retrophin to Report Fourth Quarter and Full Year 2016 Financial Results
SAN DIEGO , Feb. 15, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report fourth quarter and full year 2016 financial results on Wednesday, March 1, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss
View HTML
Toggle Summary Retrophin Appoints William Rote Senior Vice President, Research and Development
SAN DIEGO , Feb. 13, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced William "Bill" Rote, Ph.D. has been appointed senior vice president, research and development, effective immediately. Dr. Rote will oversee all aspects of the Company's R&D organization, with special focus
View HTML
Toggle Summary Retrophin Provides Corporate Update and 2017 Preview
FDA discussions on sparsentan planned for January; RE-024 advancing with Phase 3 trial for the treatment of PKAN Preliminary Full-Year 2016 Revenue of Approximately $134 Million SAN DIEGO , Jan. 09, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that, based on preliminary
View HTML